tbuckley/cabot-search huggingface dataset:
A prospective, multicenter trial of complementary and alternative medicine (CAM) utilization by patients undergoing definitive breast radiotherapy.
Authors: M. S. Moran, J. Yang, S. Ma, B. Gaudreau, S. A. Higgins, J. B. Weidhaas, L. D. Wilson, R. Peschel, D. Fass, S. Rockwell
Journal: Journal of Clinical Oncology (2011)

241 Background: A substantial number of breast cancer (BC) pts use complementary and alternative medicines (CAM), but there is a paucity of data on CAM specifically during radiation therapy (RT). The purpose of this study was to prospectively assess the utilization of CAM during RT for BC pts. Methods: 456 pts w/stage 0-III BC were accrued from 5 RT centers from 9/07-2/09. Participating MDs were advised not to discuss CAM. A validated survey instrument was administered during the last week of RT under guidance of a study nurse, which included demographics, details regarding types/doses/frequency of CAM and skin assessments by pt and nurse. Results: 360 pts were eligible for analysis (79%); median age 57 yrs; stage 0-II, 91%; white race 89%; chemotherapy 39%; hormone therapy (HT) w/ RT, 26%; &gt; college education, 59%. CAM was reported in 54% (n = 195), of which 72% reported programs/activities (i.e., Reiki, healing touch, visualization, etc.), and 66% oral/topical CAM. Only 16% reported counseling prior to starting CAM. CAM use did not differ by ethnicity, chemotherapy or stage (all p &gt; 0.05), but correlated significantly with higher education level (p = 0.0001) and inversely correlated w/ HT/RT (p = 0.015). There was a trend towards CAM use in younger pts (p = 0.069). On MVA, education (RC: 1.859; OR: 6.417, 95% CI: 2.023, 20.357, p = 0.002) and HT/RT (RC: -0.530, OR: 0.589, 95% CI: 0.357, 0.970, p = 0.038) independently predicted for CAM use. Rationale for oral/topical: 32% “improve their chance of cure”; 24% “provide treatment-related symptom relief”. For programs/activities: 31% “relaxation/stress reduction”; 11% “reduces treatment-related symptoms”. Despite these beliefs, there were no significant differences between the perception of the pts to nursing skin assessment score as a function of CAM use (p = 0.497). Conclusions: To our knowledge, this is the first and largest prospective study of CAM during RT for BC pts. Given the high prevalence of undocumented CAM use during RT, questions regarding CAM should be considered during consultation and weekly tx visits. A better understanding of CAM practices during RT will facilitate evaluation of potential interactions of CAM and RT for BC.
Faster Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation of Younger Children Compared with Older Children and Adults.
Authors: Natalja Fehse, Hartmut Kabisch, Rudolf Erttmann, Nicolaus Kroeger, Tatjana Zabelina, Petra Freiberger, Axel R. Zander
Journal: Blood (2004)
Infectious complication and recurrence after surgery for gastric cancer.
Authors: Tsutomu Hayashi, Akira Tsuburaya, Takaki Yoshikawa, Haruhiko Cho, Takashi Ogata, Toru Aoyama
Journal: Journal of Clinical Oncology (2012)

85 Background: There are many known prognostic indicators following surgery for gastric cancer. However, the impact of infectious complication on prognosis is less clear. The aim of the present study was to evaluate the relationship between infectious complication and relapse-free survival in patients undergoing potentially curative resection of gastric cancer. Methods: A consecutive series of 657 patients who underwent macroscopically curative resection between 2000 and 2005 in Kanagawa Cancer Center were retrospectively studied. Five-year relapse-free survival rates in each stages (TNM7th) were calculated. Infectious complications (≥Grage2 by Clavien-Dindo classification) were classified as pneumonia, anastomotic leakage, intra-abdominal abscess, septicaemia, colitis, pancreatic-fistula, and wound infection. Results: Mean age was 61 years; male-female ration was 4:1; the number of patients in TNM7th stages were I :389, II :93, III :116, and IV :59. Infectious complications occurred in 57 patients (8.7%) including 8.5% in stage I, 3.2% in stage II, 12.1% in stage III, and 11.9% in stage IV, respectively. Five-year relapse-free survival rates in patients without infectious complications and with infectious complications were 93.1% vs 81.6% in stage I, 84.4% and 100% in stage II, 55.8% and 28.6% in stage III, and 9% and 0% in stage IV, respectively. In stage III, patients with infectious complication had significantly poorer outcome in relapse-free survival compared with those without one (p&lt;0.05). Conclusions: This study indicates a correlation between infectious complications and cancer recurrence in advanced but localized gastric cancer. Immunologic response of the host against postoperative infection could influence the viability of microscopic residual disease. Further clinical and basic study are needed to improve outcome for this category of patients.
Influence of intra-hepatic chemotherapy on survival of patients with colorectal liver metastasis treated with hepatic resection and systemic chemotherapy.
Authors: Mohammed Kanaan, Mohammad Mozayen, Sunil Nagpal, David Wiese, David S. Eilender, T. Trevor Singh, Madan L. Arora, Sukamal Saha
Journal: Journal of Clinical Oncology (2012)

379 Background: The role of intrahepatic pump chemotherapy (HAI) in the treatment of liver metastasis is still controversial. Our study was performed to evaluate the adjunctive role of HAI in patients (pts) with colorectal liver metastasis (CLM) treated with major hepatic resection and systemic chemotherapy (Systemic Rx). Methods: A retrospective analysis was performed on pts with histologically confirmed CLM who had major liver resection and/or radiofrequency ablation and received systemic Rx with HAI and compared with pts without HAI. Primary outcome was overall survival. Exclusion criteria included a second cancer, refusal of chemotherapy, loss of follow-up and minor resection or biopsy alone. Statistical analysis was done using Kaplan-Meyer survival curves. Results: Consecutive 66 pts with CLM were analyzed, of which 13 pts were lost to follow-up. Out of 53 pts undergoing systemic Rx and major liver resection, 37 pts had HAI with 5-fluorouracil (gp A) and 16 pts had no HAI (gp B). Both groups received similar systemic Rx ( Table 1). There was no HAI related mortality in gp A. Pts with minimum follow-up of 3 years were included for survival analysis. The overall 3-year survival of gp A was 36% (12 pts out of 33) compared to 23 % (3 pts out of 13 pts) in gp B. Due to small sample size statistical significance was not achieved. Conclusions: Pts with CLM who undergo systemic Rx with HAI along with major hepatic resection or ablation may survive longer than pts with systemic Rx without HAI. A larger multicenter study is warranted. [Table: see text]
A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis.
Authors: Efstathios Kastritis, Maria Roussou, Magdalini Migkou, Konstantinos Pamboukas, Maria Gavriatopoulou, Dimitrios Gogos, Konstantinos Liapis, Eurydiki Michalis, Sosana Delimpasi, Erasmia Psimenou, Savvas Toumanidis, Sofocles A. Kontoyannis, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood (2009)
Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial.
Authors: T. B. Julian, J. P. Costantino, F. A. Vicini, J. R. White, K. A. Winter, D. W. Arthur, R. R. Kuske, R. Rabinovitch, D. S. Parda, E. P. Mamounas, W. J. Curran, N. Wolmark
Journal: Journal of Clinical Oncology (2011)

1011 Background: APBI is now being used clinically and is being evaluated in 6 clinical trials in which several forms of fractionated external beam for APBI are being used. Recent publications and presentations from small single-institution series have reported significant short-term toxicities related to 3-D CEBT, a type of APBI under evaluation in NSABP B−39/RTOG 0413. Given those results, we believe it necessary to report the current levels of toxicity in the 3−D conformal portion of the APBI arm of our trial. Methods: NSABP B−39/RTOG 0413, a multi-institutional randomized phase III trial, compares whole-breast irradiation with APBI. Included is an electronic CT- data submission process that serves as the basis of a rigorous QA program used in all 3 types of APBI, assuring dosimetric compliance. Closely monitored data on patients randomized to the APBI arm and undergoing 3−D CEBT were reviewed for overall toxicity, specifically for toxicity related to fibrosis-cosmesis and fibrosis-deep connective tissue, based on CTCAEv3.0 and NSABP/RTOG CTCAE criteria. Results: 3,862 patients are enrolled (89.8% of target accrual). Toxicity data are available for 1386 patients randomized to APBI who have received 3−D CEBT, with 974 of the latter group in their 3rd year of follow-up. With a mean time on study of 41.0 months, no significant toxicity-related issues have been raised. The rates of fibrosis-cosmesis and fibrosis-deep connective tissue toxicities are: Grade 2 ≤12%, Grade 3 ≤3% and Grade 4/5 =0% for the 3-D CEBT used in the trial. Conclusions: Contrary to findings in recent published reports the 3-D conformal APBI toxicity rates in our trial are acceptably low. Our trial surpasses others reported in patient number and length of follow-up, emphasizing the importance of large phase III randomized trials with rigorous QA to determine treatment outcomes and avoid the bias that can arise from small single-institution series. The continuation of accrual to this trial is critically important so that APBI efficacy, long-term toxicity, and QOL outcomes can be accurately assessed. Supported by NCI-U10-CA-12027, U10-CA−37377, U10-CA−69974, U10-CA−69651, and U10-CA−21661.
SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy
Authors: Mohamed Amin Ahmed, Nathan Fowler, Long Ma, Mansoor Noorani, Karishma Phansalkar, Fredrick B. Hagemeister, Jorge E. Romaguera, Luis Fayad, Alma Rodriguez, Felipe Samaniego, Michelle Fanale, Michael Wang, Yasuhiro Oki, Francesco Turturro, Jason R. Westin, Larry W. Kwak, Loretta J. Nastoupil, Chan Cheah, Lei Feng, Eric M Rohren, Richard E. Davis, Sattva S. Neelapu
Journal: Blood (2014)
Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial.
Authors: W. J. Gradishar, D. Krasnojon, S. V. Cheporov, A. Makhson, G. M. Manikhas, A. Clawson, P. Bhar
Journal: Journal of Clinical Oncology (2011)

275 Background: We previously reported the results of a phase II study evaluating the efficacy and safety of three different dosing regimens of ab-pac and docetaxel for the first-line treatment of MBC (Gradishar et al. J Clin Oncol. 2009;27:3611-3619). Here we report final OS outcomes. Methods: Patients (N = 300) with previously untreated MBC were randomized to 1 of 4 treatment arms (arms A–D listed in table). A step-down statistical approach was used for pairwise comparisons of treatment groups. Results: Patients (N = 300) with previously untreated MBC were randomized to 1 of 4 treatment arms (arms A–D listed in table). A step-down statistical approach was used for pairwise comparisons of treatment groups. These OS data were consistent with the investigator assessment of overall response rates (ORR) and progression-free survival (PFS) that were previously published. Rates of grade (gr) 3 sensory neuropathy (SN) were 21%, 9%, 22% and 12%, respectively in arms A, B,C, and D (p= 0.082). There were no cases of gr 4 SN. The median times to improvement to ≤ gr 2 SN were 22, 22, and 20 days for arms A, B, and C and 37 days for arm D. Gr 3/4 neutropenia occurred less frequently with ab-pac vs docetaxel (gr 3: 39, 20, 35, and 19% in arms A,B,C, and D, respectively; gr 4: 5, 5, 9, and 75%, p &lt; .001 for gr 4). Conclusions: Ab-pac qw 3/4 at 150 mg/m 2 resulted in a 33.8 mo OS, a longer OS than historically achieved with taxane monotherapy in MBC. The 150 mg/m 2 qw 3/4 dosing regimen provided the best clinical outcome in this phase II trial in patients with MBC. [Table: see text]
Self-aggregating 1.8 kDa polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides
Authors: Manuela Chiper, Nassera Tounsi, Ryszard Kole, Antoine Kichler, Guy Zuber
Journal: Journal of Controlled Release (2016)
Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non‐small cell lung cancer: results of a prospective cardiovascular long‐term study
Authors: Markus S. Anker, Nicole Ebner, Bert Hildebrandt, Jochen Springer, Marianne Sinn, Hanno Riess, Stefan D. Anker, Ulf Landmesser, Wilhelm Haverkamp, Stephan von Haehling
Journal: European Journal of Heart Failure (2016)
A single-institution survey of de novo secondary malignancies in patients occurring after orthotropic liver transplantation.
Authors: Quentin Gillebert, Mohamed Bouattour, Francois Durand, Claire Francoz, Valerie Paradis, Chantal Dreyer, Jacques Belghiti, Eric Raymond, Sandrine J. Faivre
Journal: Journal of Clinical Oncology (2012)

297 Background: We aim to evaluate in our institution the incidence of de novo malignancies following orthotopic liver transplantation (OLT) and their impact the prognosis of patients (pts). Methods: Pts treated with OLT from August 1991 To March 2009 were considered in this analysis. All pts data had been prospectively recorded in the database of French “Bio-medecine Agence”. Pts were considered for this analysis only if they survived at least 3-months after. Occurrence of de novo malignancies we analyzed and additional data (including immunosuppressive profile, type of cancer, potential independent risk factors of cancers, prognosis and the influence of immunosuppression protocols or risk factors on occurrence of cancers) were collected in patients who developed secondary cancers. Results: A total of 833 patients who underwent OLT were considered for this analysis. With a median follow-up of 7.9 years, 72 pts developed 92 de novo malignancies. The overall incidence of cancers in our population was 10.4% occurring with a median time of 6.1 years following OLT. Sixteen pts developed 2 different types of cancer and 2 pts had more than 3 tumor types. Before 12/1998, immunosuppression was primarily based on cyclosporine, steroids and/or azathiopirine, and since 01/1999 was switched to tacrolimus. Incidence of cancers regarding these two periods is summarized in the table. Before 1998, only 3 pts (17.6%) with secondary cancer had prior history of alcoholism and/or smoking compared to 27 pts (50%) after 1999. Thirty one deaths were observed and the median overall survival (OS) after the time of diagnosis of secondary malignancy was 5.62 years. Conclusions: The risk of de novo cancer after OLT is similar to reported series. History of smoking and alcohol use, increase the incidence of de novo malignancies especially head and neck and lung cancers however, immunosuppression type may not interfere with this risk. [Table: see text]
Necrotizing granulomatous disease in patients receiving imatinib mesylate treatment for gastrointestinal stromal tumors (GIST).
Authors: N. Meidenbauer, A. Stegmann, A. Mackensen, A. Agaimy
Journal: Journal of Clinical Oncology (2011)

e20525 Background: Imatinib mesylate (IM) represents the standard treatment for patients with BCR-ABL–positive chronic myelogenous leukemia (CML) and is the first line adjuvant and palliative treatment modality for those with disseminated or inoperable gastrointestinal stromal tumor (GIST). IM is not known to be associated with an elevated risk for tuberculosis, since only five patients have been reported to date who developed tuberculosis during or after IM treatment. Methods: We describe here a series of 3 patients (45-79 yrs of age) with GIST who developed necrotizing (caseating) granulomatous disease during IM treatment. Mean duration of treatment with Imatinib was 22 (range 9-49) months. Results: Enlarged lymph nodes with increased metabolism in 18-fluorodeoxyglucose-positron emission tomography (FDG-PET)-CT -scans were detected and resected in 3 GIST patients under treatment with IM. Affected sites were subcarinal/ mediastinal (1), mediastinal/ supraclavicular (1) and periparotideal cervical (1) lymph nodes. Histologic examination revealed necrotizing granulomatous disease suggestive of infection with M. tuberculosis or sarcoidosis. Sputum examination for acid fast bacilli was negative in all patients and DNA was negative for M. tuberculosis and other mycobacteria in two cases. In one GIST patient M. tuberculosis was detected by PCR in the lymph node who was then successfully treated by antituberculous agents. The other patients received no antituberculous therapy and showed no evidence of of active tuberculosis during follow up. White blood cell and total lymphocyte counts remained within the normal range throughout treatment with IM. Conclusions: Our observations underline the necessity to sample enlarged or metabolic active lymph nodes developing during IM treatment for timely diagnosis and appropriate treatment of these rare complications. Watch and wait strategy appears to be safe for those lesions being negative for M. tuberculosis by PCR. In summary, more studies are needed to clarify the potential causal relationship between IM treatment and granulomatous disease, and to explore the pathogenesis of lesions that were negative for M. tuberculosis.
Positive surgical margins and biochemical recurrence in obese patients with intermediate- and high-grade prostate cancer with radical prostatectomy.
Authors: Emma Holliday Ramahi, Katherine Cox Ansley, Matthew W. Jackson, Joseph W. Basler, Fei Du, Gregory P. Swanson
Journal: Journal of Clinical Oncology (2012)

50 Background: The relationship between obesity and prostate cancer outcomes is unclear. We performed a retrospective cohort study to determine the effect of body mass index (BMI) on a cohort of patients with intermediate to high grade prostate cancer treated with radical prostatectomy (RP). Methods: Our retrospective study cohort included 582 men diagnosed with Gleason 7-10 prostate cancer between 1998 and 2008 and treated with RP at a single institution. Patients were stratified into four groups on the basis of their BMI at the time of prostate cancer diagnosis (&lt;25, 25-30, 30-35 or &gt;35). The primary endpoints for comparison were biochemical failure free survival (BFFS) and the incidence of positive margins. PSA &gt;0.2 ng/dl was used to define biochemical failure. Results: After adjusting for age, Gleason score, pre-treatment PSA and the presence of diabetes, we found patients with increasing BMI had an increased frequency of biochemical failure after RP. Compared to patients with a normal BMI (&lt;25), patients with BMI 25-30, 30-35, and &gt;35 had 1.82 (1.12, 2.97; p = 0.02), 2.14 (1.33, 3.45; p = 0.002) and 2.29 (1.1, 4.78; p = 0.03) times higher rates of biochemical failure, respectively. We additionally found increased positive margins after RP in patients with a BMI 30-35 and &gt;35 (41.4% and 45.5%, respectively) when compared to patients with a BMI of &lt;25 and 25-30 (33.3% and 28.9%, respectively); p = 0.02. Conclusions: Patients with increasing BMI seem to be at significantly increased risk for biochemical failure following RP potentially due to the increased technical difficulty of the surgery and increased incidence of positive margins. [Table: see text]
Single institution's data on triple-negative breast cancer in African-American women.
Authors: K. A. Abuelgasim Ahmed, Z. Y. Ghanem, A. Aggarwal
Journal: Journal of Clinical Oncology (2011)

188 Background: Although African-American women (AAW) have lower incidence of breast cancer, they have higher breast cancer related mortality compared to Caucasian women (CW). The incidence of triple-negative breast cancer (TNBC) is as high as 20%-26% in AAW compared to 15% in CW. The incidence of TNBC is higher in women younger than age fifty, compared to non-triple-negative breast cancer (NTNBC). TNBC also presents at a more advanced stage. We studied the characteristics of TNBC in AAW diagnosed at Howard University Hospital. Methods: We identified all the newly diagnosed invasive breast cancer patients who had assessable data for ER, PR, and HER2/neu status from January 2004 to December of 2009, by reviewing our institution’s tumor registry. ER, PR positivity was determined if equal or more than 10% of the tumor cells tested positive by IHC stain. Her-2/neu was determined to be positive if the IHC stain was (3+). Tumors that tested equivocal (2+) were sent for FISH testing. Age and stage data was collected on all patients. Results: Between Jan 2004 and Dec of 2009, a total of 294 AAW were diagnosed with invasive breast cancer and had enough data for evaluation. Seventy four (25%) patients had TNBC. Among those, 22 patients (30%) were less than 50 years old at the time of diagnosis, compared to 57 patients (26%) of the NTNBC (P-value = 0.5). Fifty two (74%) patients with TNBC were diagnosed with early stage disease (stages 1 and 2), compared to 150 (73%) of the NTNBC (P-value = 1); with 4 patients with TNBC and 15 patients with NTNBC had missing staging. (See table.) Conclusions: The incidence of TNBC in our cohort of AAW is 25% which is the same as the incidence reported in the literature. Even though TNBC patients are known to have worse prognosis, this may not be attributed to the stage of the disease at presentation or the age of the patient since both group showed no statistically significant difference in both variables. [Table: see text]